The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACRX | +8.24% | -96.95% | -50.23% | -99% |
| S&P | +15.06% | +95.03% | +14.29% | +407% |
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Gross Margin | 65.84% | 0.0% |
| Market Cap | $9.44M | -37.6% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 13 | -13.3% |
| Net Income | -$3.49M | 8.8% |
| EBITDA | -$3.69M | 13.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.79M | -49.4% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.50M | -0.4% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -55.00% | 9.4% |
| Return On Invested Capital | -26.46% | -18.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.95M | 36.1% |
| Operating Free Cash Flow | -$2.95M | 36.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.14 | 0.93 | 1.05 | 1.41 | 51.79% |
| Price to Sales | 58.59 | 79.91 | 481.58 | 588.55 | 1404.68% |
| Price to Tangible Book Value | 1.14 | 0.93 | 1.05 | 1.41 | 51.79% |
| Enterprise Value to EBITDA | -4.76 | -1.63 | -4.85 | -4.22 | 13.98% |
| Return on Equity | -111.9% | -117.7% | -106.8% | -117.6% | -0.71% |
| Total Debt | $6.53M | $0.00M | $6.53M | $6.50M | -0.43% |
ACRX earnings call for the period ending March 31, 2020.
ACRX earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
